HMP Global

Oncology Learning Network

Health EN ↓ 191 episodes

Podcast by HMP Global

Be sure to visit the podcast's website and support the creator: soundcloud.com

Author

HMP Global

Category

Health

Podcast website

soundcloud.com

Latest episode

Nov 4, 2026

Where to listen?

Podcasts in the app Replaio Radio Coming soon

Podcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts

Get it on Google Play Install for free Android 10M+ downloads · 4.7+ rating iOS soon

Episodes

Dr Abou-Alfa Discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer 03.01.2020

Recapping a late-breaking abstract from ASCO 2019, Dr Abou-Alfa discusses POLO Trial, Olaparib to Treat gBRCA-mutated, Metastatic Pancreatic Cancer. Since the recording of this podcast, olaparib has been approved by the FDA as maintenance therapy for gBRCA-mutated metastatic pancreatic cancer as of December 30, 2019.

Effect of Cost on Adherence to Therapy in Patients With Breast Cancer 30.12.2019

Dawn Hershman, MD, MS, Professor of Medicine and Epidemiology at Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, discusses how the cost of breast cancer treatment is directly associated with rates of adherence, and explains why financial factors matter in treatment decisions.

Encouraging Clinical Trial Participation in Patients With Cancer 18.12.2019

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the benefits of clinical trial participation for patients with cancer.

Updates in the HER2 Breast Cancer Therapy Space - Part I 18.12.2019

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.

Updates in the HER2 Breast Cancer Therapy Space - Part II 18.12.2019

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, talks about the latest data being presented on HER2 breast cancer therapy options.

Shanu Modi, MD, Discusses the DESTINY-Breast01 Trial 18.12.2019

Dr Modi discusses the basis, clinical significance, and findings of the DESTINY-Breast04 trial of DS-8201a therapy for HER2-low breast cancer.

Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma 17.12.2019

Novel BTK Inhibitor Shows Promising for Mantle Cell Lymphoma by HMP Global

DS-8201a Shows Promise in Treatment of HER2-Positive Breast Cancer 12.12.2019

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, spoke with Oncology Learning Network about data that was presented regarding the use of DS-8201a in the treatment of HER2-positive breast cancer.

Treating Early Stage, HER2-Positive Breast Cancer 12.12.2019

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, talks about advancements made in the treatment of patients with early stage, HER2-positive breast cancer.

The Promising Role of Tucatinib in HER2-Positive Breast Cancer Therapy 12.12.2019

Sherene Loi, MD, PhD, Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the HER2CLIMB study and the promising role of tucatinib in the treatment of metastatic, HER2-positive breast cancer.

Evolution of the treatment landscape for Tenosynovial Giant Cell Tumors 21.11.2019

Jonathan Trent, MD, PhD, Professor and Associate Director for Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami, Florida discusses the evolution of the current treatment landscape for tenosynovial giant cell tumors.

Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors 08.11.2019

Pexidartinib Demonstrates Great Tumor Response in Tenosynovial Giant Cell Tumors by HMP Global

Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer 29.10.2019

Niraparib After First-Line Chemotherapy New Standard of Care for Advanced Ovarian Cancer by HMP Global

Amer Zeidan, MBBS, MHS, discusses Myelodysplastic Syndrome(MDS)at 2019 ASH MHM 24.10.2019

Amer Zeidan, MBBS, MHS, Yale University, discusses diagnosis and treatment of Myelodysplastic Syndrome(MDS)at 2019 ASH Meeting on Hematologic Malignancies

Newer Treatment Options for Patients With Hodgkin Lymphoma 18.10.2019

Newer Treatment Options for Patients With Hodgkin Lymphoma by HMP Global

Treating Newly Diagnosed Patients With MCL 17.10.2019

Treating Newly Diagnosed Patients With MCL by HMP Global

FOxTROT Trial Supports Preoperative Chemotherapy in Colon Cancer, with Matthew Seymour, MD 01.10.2019

Matthew Seymour, MD, discusses the FOxTROT trial that supports preoperative chemotherapy as a treatment with multiple, clear benefits for patients with colon cancer.

Isatuximab Triplet Encouraging for Relapsed/Refractory Multiple Myeloma 12.09.2019

Isatuximab Triplet Encouraging for Relapsed/Refractory Multiple Myeloma by HMP Global

Neratinib Plus Capecitabine Improves PFS in HER2-Positive Breast Cancer 31.07.2019

Neratinib Plus Capecitabine Improves PFS in HER2-Positive Breast Cancer by HMP Global

Adding Ribociclib to Endocrine Therapy Improves OS in Young Patients With Advanced Breast Cancer 19.06.2019

Sara A. Hurvitz, MD, University of California-Los Angeles Jonsson Comprehensive Cancer Center, discusses the background, findings, and clinical significance of the MONALEESA 7 trial, the findings of which were presented at the 2019 ASCO Annual Meeting.

Ixazomib Promising Maintenance Therapy Option for Multiple Myeloma 11.04.2019

Ixazomib Promising Maintenance Therapy Option for Multiple Myeloma by HMP Global

Novel Immunotherapy Approaches for Multiple Myeloma 11.04.2019

Novel Immunotherapy Approaches for Multiple Myeloma by HMP Global

Earlier Daratumamab Use Feasible for Relapsed/Refractory Multiple Myeloma 11.04.2019

Earlier Daratumamab Use Feasible for Relapsed/Refractory Multiple Myeloma by HMP Global

Survey Results Show Oncologists Want to Learn More About the Needs of LGBTQ Patients 04.04.2019

Matthew B. Schabath, PhD, discusses the results of his team’s national survey, which was conducted to identify potential gaps in attitudes, knowledge, and institutional practices toward LGBTQ patients with cancer.

Daunorubicin Decreases Long-Term Cardiomyopathy Risk in Childhood Cancer Survivors 12.03.2019

Daunorubicin Decreases Long-Term Cardiomyopathy Risk in Childhood Cancer Survivors by HMP Global

Listen to the Oncology Learning Network podcast in Replaio

Radio and podcasts in one app - free, with no sign-up. Install today and do not miss the launch

Get it on Google Play

Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.